April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
New Intraocular Drug Delivery Device
Author Affiliations & Notes
  • S. A. Molokhia
    Ophthalmology,
    University of Utah, Salt Lake City, Utah
  • H. J. Sant
    Mechanical Engineering,
    University of Utah, Salt Lake City, Utah
  • M. C. Hanson
    Bioengineering,
    University of Utah, Salt Lake City, Utah
  • R. M. Burr
    Bioengineering,
    University of Utah, Salt Lake City, Utah
  • A. E. Poursaid
    Bioengineering,
    University of Utah, Salt Lake City, Utah
  • C. J. Bishop
    Bioengineering,
    University of Utah, Salt Lake City, Utah
  • J. M. Simonis
    Ophthalmology,
    University of Utah, Salt Lake City, Utah
  • B. K. Gale
    Mechanical Engineering,
    University of Utah, Salt Lake City, Utah
  • B. K. Ambati
    Ophthalmology,
    University of Utah, Salt Lake City, Utah
  • Footnotes
    Commercial Relationships  S.A. Molokhia, None; H.J. Sant, None; M.C. Hanson, None; R.M. Burr, None; A.E. Poursaid, None; C.J. Bishop, None; J.M. Simonis, None; B.K. Gale, patent application, P; B.K. Ambati, patent application, P.
  • Footnotes
    Support  Supported by University of Utah Technology Commercialization Program. US Patent Pending
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 5974. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. A. Molokhia, H. J. Sant, M. C. Hanson, R. M. Burr, A. E. Poursaid, C. J. Bishop, J. M. Simonis, B. K. Gale, B. K. Ambati; New Intraocular Drug Delivery Device. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5974.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The objective was to develop a new sustained release, refillable intraocular drug delivery system that fits in the capsular lens for potential multi drug use. The approach is to have a capsule ring with a drug reservoir of 100µl volume that fits within the lens capsular bag and is inserted through a 2.75 mm wound (standard cataract incision size)

Methods: : The capsule drug ring (CDR) prototypes were manufactured using computer numerical control machine (CNC, Haas Automation Inc., CA). The shell for the drug reservoir was made of PMMA (Perspex, Goodfellow Corporation, PA). A Perspex sheet of 2.0 mm thickness was used as the starting material. The preliminary check valves were made using a silicone elastomer (C6540, Dow Corning Corporation, MI) for a standard 27 gauge ophthalmic cannula to fill the reservoir. The CDR at this point has one face open for a semi permeable membrane to adhere on its surface. Passive permeability studies in vitro were performed in a side-by-side diffusion cell using hydrophilic or hydrophobic semi permeable membranes of different pore sizes and Avastin® as the drug of interest. The Avastin® samples were collected from the receiver compartment at predetermined time and assayed by an ELISA protocol. Polyvinyl alcohol (PVA) 87-89% hydrolyzed (molecular weight 146-158 kDa) of high viscosity was investigated as the drug carrier.

Results: : A circular ring shape prototype device was developed to maximize the volume available in the capsular bag and have a drug reservoir of 100µL. An early stage prototype CDR model was manufactured. Two valves are included in the design for potential use of multi-drug disease treatment. The semi permeable membranes showed a permeability coefficient value (P) in the order of 10-7 cm/sec. The smaller pore size membrane showed almost two-fold lower P value when compared to the larger pore size of the same semi permeable membrane. PVA had a viscosity value of approximately 50-times higher than Avastin® at a similar concentration (50 mg/ml) and a shear rate of 10 sec-1

Conclusions: : The results demonstrate successful manufacturing of a PMMA shell device with a semi permeable membrane. This shows the potential of the CDR device as an implantable ocular device for drug delivery. The use of CE 25 nm along with the high viscosity PVA could provide a sustained release profile for Avastin®.

Keywords: intraocular lens • age-related macular degeneration • small incision cataract surgery 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×